The genetic testing
industry, all in one place.

St. Luke's Medical Center has launched a dedicated Cancer Genomics Service, expanding precision oncology access in the Philippines.

Genomics experts remain deeply divided over which conditions should trigger newborn sequencing, stalling consensus on national guidelines.

FDA clears Guardant Health's first combined genomic-epigenomic liquid biopsy panel, sending shares up 25% and reshaping the ctDNA testing landscape.

Ambry Genetics has unveiled GenomeNext™, a whole genome sequencing test solution designed to improve diagnostic yields for rare disease patients.

MENA nations are investing in homegrown genomic infrastructure to reduce dependence on Western datasets and drive regional precision medicine.

Gene Solutions is pursuing a Hong Kong IPO to accelerate its genomic testing expansion across Southeast Asia's fast-growing healthcare markets.

NeoGenomics launches its FDA-approved PTEN companion diagnostic test, prompting analysts to revisit whether NEO shares are underpriced.

Standard cancer genetic testing protocols may fail to detect the majority of inherited gene variants, raising urgent questions about clinical completeness.